Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 15/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075647 | 0.85 | BUB1 (0.53) | BUB1 | |
| SCHEMBL27075643 | 0.82 | BUB1 (0.52) | BUB1EGFRERBB2 | |
| SCHEMBL27075652 | 0.82 | BUB1 (0.46) | ABCG2BUB1 | |
| SCHEMBL27075644 | 0.82 | BUB1 (0.55) | BUB1 | |
| SCHEMBL27075649 | 0.80 | MEN1 (0.47) | NTRK1 | |
| SCHEMBL31356301 | 0.73 | ABCG2 (0.48) | KDM1AABCG2NTRK1EGFR | |
| SCHEMBL31485477 | 0.72 | ABCG2 (0.47) | KDM1AABCG2NTRK1EGFR | |
| SCHEMBL10571080 | 0.71 | KDM1A (0.53) | KDM1AABCG2NTRK1EGFR | |
| SCHEMBL27075646 | 0.71 | BUB1 (0.52) | BUB1 | |
| SCHEMBL27075638 | 0.70 | HTR6 (0.45) | BUB1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891390-B1 | 3-substituted amino-2-arylpyrrolo[2,3-c]pyridines as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891390-B1 | 3-substituted amino-2-arylpyrrolo[2,3-c]pyridines as CK2 inhibitors | CSNK2A3, CSNK2A2, CSNK2A1 | KDM1A 3593/4885ABCG2 3973/4885NTRK1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.